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Hospitalisation for lower 
respiratory tract infection 
is associated with an increased 
incidence of acute myocardial 
infarction and stroke in tropical 
Northern Australia
A. Pak1, D. P. Eisen2, E. S. McBryde1 & O. A. Adegboye1,3* 
Acute respiratory infections appear to precipitate vascular events. Acute myocardial infarction (AMI) 
and stroke are the leading cause of death and disability globally. This study was based on a cohort 
of patients admitted to Townsville University Hospital between January 2006 and December 2016. 
Using a self-controlled case series design, we investigated the risk of AMI or ischaemic stroke after 
an episode of pneumonia. We defined the ‘risk interval’ as the first 14 days after hospitalisation for 
pneumonia and the ‘control interval’ as  one year before and one year after the risk interval. Among 
a population (N = 4557) with a median age of over 70, a total of 128 AMI and 27 stroke cases were 
identified within 1 year of an episode of pneumonia in this study. Ten and two admissions occurred 
during the risk interval, while 118 and 25 admissions occurred during the control period. The relative 
incidence ratios (RIR) of AMI  increased after an episode of pneumonia  (RIR=4.85, 95% confidence 
interval (CI) 2.44–9.67). The risk for stroke after the exposure period of 14 days was 4.94 (95% CI 
1.12–21.78) considering only the first stroke incidence. The RIR results for AMI and stroke were not 
altered by adjusting for age, sex or Indigenous status. The risk of AMI and stroke were significantly 
higher two weeks after an episode of pneumonia.
Cardiovascular disease (CVD) is the number one cause of death globally with an estimated 17.9 million deaths 
(about one-third of global deaths) in  20161. When combined, the acute vascular events of acute myocardial 
infarction (AMI) and stroke are the leading cause of death (85% of all CVD deaths) and disability  globally1–5. 
The main risk factors for vascular disease are chronic and predominantly associated with lifestyle (smoking and 
obesity), diabetes, hypertension and familial  factors6–8. These severe vascular events also appear to be precipitated 
acutely by lower respiratory tract  infections9,10. As lower respiratory tract infections (LRTIs) are common, an 
awareness of the potential for subsequent AMI and stroke is required to direct additional preventive strategies 
such as vaccination (to prevent pneumonia and viral LRTI) and the use of anti-platelet therapy. The traditional 
focus on primary cardiovascular risk factor prevention could be complemented by secondary prevention targeted 
at the post-infective period.
In this study, we sought to quantify the risk of AMI and stroke in patients living in the tropical regions of 
Northern Australia after an episode of hospitalisation due to lower respiratory tract infections (LRTI), caused by 
both bacterial pneumonia and influenza. The database used includes a large proportion of Australian Indigenous 
peoples, so we’re able to explore whether additional factors, including Indigenous status influence this association.
We have employed a self–controlled case series methodology to optimally investigate associations between 
transient exposures and linked  events11,12. This methodology allows for minimisation of fixed confounders.
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Results
Out of a total of 4557 admissions with pneumonia as the primary diagnosis, we identified 128 unique AMI admis-
sions from 117 patients and 27 unique stroke admissions from 26 patients, which occurred within an individual 
2-year period determined by the discharge date of pneumonia-related hospitalisation (Fig. 1). Table 1 presents 
the baseline characteristics of the included patients who had an AMI/stroke episode associated with severe LRTI 
exposure and those with LRTI only during the 2-year period requiring hospitalisation. Our study population 
consists of predominantly older adults with a mean age of 77.2 years, 69.4 years and 68.3 years, respectively, for 
LRTI-AMI, LRTI-stroke and LRTI cohorts. Females accounted only for 42.7% of patients who had AMI after 
LRTI exposure, but there were more females than males with stroke after LRTI exposure (57.7%) and 47.6% 
among LRTI only patients. A significant minority (n = 38, 32.5%) of patients identified themselves as Aboriginal 
and Torres Strait Islander (Indigenous) peoples in the LRTI-AMI and a lesser number in the LRTI-stroke (n = 3, 
11.5%) cohorts. The majority of patients were admitted through the hospital’s emergency department (ED), 87 
(74.4%) for AMI, 24 (92.3%) for stroke and 549 (71.0%) for LRTI only. When considering conventional risk 
factors for cardiovascular disease, many of the patients in the LRTI-AMI and LRTI-stroke smoked (74.4% vs 
50.0%), (69.2% vs 50.0%) were hypertensive and (7.0% vs 0%) had dyslipidaemia, while 54.7% and 38.5% had 
diabetes, respectively. These statistics were higher for patients with LRTI only, 70.8% smoked, 70.2 were hyper-
tensive, and 18.1 had dyslipidaemia. Aside from a difference in patient’s age (older) and length of stay (longer), 
those who had AMI/stroke associated with LRTI exposure during the 2-year period were otherwise not different 
from patients who did not suffer these diseases.
We found strong evidence of an increased risk of AMI after hospitalisation for LRTI, with the most substantial 
effect in the first 2 weeks. We recorded nine cases of AMI occurring in the “at-risk” period after exposure and 
108 episodes in the control period (Fig. 2A). The results in Table 2 showed that the RIRs for AMI in Model I 
were 4.85 (95% CI 2.44–9.67) and 4.91 (95% CI 2.55–9.46) for first AMI events and all AMI events respectively.
Considering the first event only, there were two admissions for stroke during the “at-risk” 14–day interval after 
the exposure and 24 stroke episodes during the control period (Fig. 2B). Although the number of patients with 
a stroke episode was small which widened the confidence intervals of the estimates, we found that the rates of 
stroke were substantially higher after the exposure to LRTI as presented in Table 2. The relative incidence ratios 
(RIR) for the main models (Model 1) with the exposure period of 14 days were 4.94 (95% CI 1.12–21.78) and 4.61 
(95% CI 1.05–20.22) accounting for first stroke events and all stroke events respectively. For the models with an 
additional 14-day exposure period (Model 2), the incidence ratios of 5.12 (95% CI 1.16–22.70) and 4.76 (95% CI 
Figure 1.  AMI and Stroke admissions included in the study.
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1.08 – 20.98) for the interval of 1–14 days were statistically significant for first stroke events and all stroke events, 
respectively. However, we observed no statistically significant increase in the relative incidence ratios in the longer 
exposure interval of 15–28 days. Furthermore, in Model 3, the exposure period was extended to 3 months and 
RIRs were 1.63 (95% CI 1.00–2.66) and 3.94 (95% CI 1.62–9.56) for the first AMI and stroke events, respectively.
To test the validity of our results, we performed sensitivity and robustness checks. The sensitivity analysis 
showed that our results were largely robust to a different model and sample specifications (Table 2). Changing 
Table 1.  Baseline characteristics of patients who had an AMI/stroke during 2-year period associated with 
LRTI exposure at the first event. LOS Length of hospital stay. a Percentages of presence of comorbidity vs. 
absence of comorbidity.
Baseline characteristic LRTI–AMI LRTI–stroke LRTI only
Number of patients, n 117 26 773
Events within 14 days interval 9 2 NA
LOS in days: mean ± SD 7.2 ± 7.3 14.0 ± 15.0 5.7 ± 9.0
Age in years: mean ± SD 69.4 ± 15.4 77.2 ± 10.7 68.3 ± 16.2
Age group, n (%)
20–39 years 1 (0.9) 0 (0.0) 48 (6.2)
40–59 years 34 (29.1) 2 (7.7) 161 (20.8)
60–84 years 57 (48.7) 18 (69.2) 442 (57.2)
85+ years 25 (21.4) 6 (23.1) 122 (15.8)
Gender, n (%)
Male 67 (57.3) 11 (42.3) 405 (52.4)
Female 50 (42.7) 15 (57.7) 368 (47.6)
Indigenous status, n (%)
Indigenous 38 (32.5) 3 (11.5) 140 (18.1)
Non–indigenous 79 (67.5) 23 (88.5) 633 (81.9)
Comorbidity, n (%)a
Hypertension 81 (69.2) 13 (50.0) 543 (70.2)
Dyslipidaemia 7 (6.0) 0 (0) 140 (18.1))
Diabetes 64 (54.7) 10 (38.5) 337 (43.6)
Smoking 87 (74.4) 13 (50.0) 547 ( 70.8)
Admission source, n (%)
Emergency department 87 (74.4) 24 (92.3) 549 (71.0)
Outpatient department 2 (1.7) 0 (0.0) 113 (14.6)
Transferred from another hospital 17 (14.5) 1 (3.8) 21 (2.7)
Others 11 (9.4) 1 (3.8) 90 (11.6)
Figure 2.  Plot of individual patient-level observation period and the 14 days LRTI risk periods (shaded). Days 
since exposure is the number of days before or after hospitalisation for LRTI.
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the control interval by assigning a 7 and 14-day pre-exposure period slightly reduced the incidence ratios for 
both LRTI-AMI and LRTI-stroke. However, excluding seven stroke episodes with the date of death within 
90 days made the results for LRTI-stroke insignificant, which was likely due to the reduction in sample size. 
For the model which accounted for patients who died shortly after AMI, the results were robust, although the 
confidence intervals are slightly wider.
In addition to sensitivity analysis, we performed robustness checks by examining associations between LRTI 
exposure and other health outcomes such as admissions to hospital for complications of diabetes and cancer 
diagnosis (Table 2). Similar to Kwong et al.13, we identified hospital admissions related to diabetes with compli-
cations using primary diagnosis based on ICD-10-AM codes E10, E11, E13, and E14. The number of patients 
in the sample was similar to the number of AMI patients. The RIRs for LRTI-diabetes first event (1.47, 95% CI 
0.46–4.63) and LRTI-diabetes all events (1.21, 95% CI 0.45–3.26) were not statistically significant. Similarly, we 
found no evidence of an increased risk of cancer (ICD-10-AM codes C00-C75 excluding only C34 that encodes 
for lung cancer) after LRTI.
We explored the heterogeneity in the incidence ratios due to LRTI exposure with respect to gender, age, and 
indigenous status by including an interaction term (Table 3). We also performed a likelihood ratio test to test 
whether or not an interaction term should be included in the model. For stroke patients, we did not observe a 
significant interaction between exposure period and Indigenous status, and no results were reported for models 
with heterogeneous effects for age and Indigenous status because no variation was observed in the variables due 
to the small sample size (Table 3).
Discussion
In this study, we provide evidence that, in a population of elderly patients living in the Australian tropics, there 
is a transient increase in the risk of AMI or stroke after hospitalisation for severe LRTI. The “at-risk” interval, in 
which the increased risk of AMI/stroke persisted, was 14 days. The incidence of admissions for AMI and stroke 
were more than four and seven times, respectively, during the 14–day interval after the LRTI stimulus. Our 
Table 2.  Relative incidence ratios (RIR) for AMI/stroke after LRTI exposure with sensitivity/robustness 
checks. ***Significant at 1%; **significant at 5%; *significant at 10%.
Model









Exposure 1–14 days 4.85*** (2.44–9.67) 4.91*** (2.55–9.46) 4.94** (1.12–21.78) 4.61** (1.05–20.22)
Model 2 (with extended exposure period)
Exposure 1–14 days 4.85*** (2.43–9.67) 4.90*** (2.54–9.44) 5.12** (1.16–22.70) 4.76** (1.08–20.98)
Exposure 15–28 days 0.98 (0.24–3.97) 0.88 (0.22–3.57) 2.21 (0.29–16.95) 2.10 (0.28–15.97)
Model 3
Exposure 1–91 days 1.63* (1.00–2.66) 1.51* (0.94–2.44) 3.94*** (1.62–9.56) 3.54*** (1.48–8.46)
Sensitivity checks for Model 1
Control for pre-exposure 
period (7 days) 4.79*** (2.41–9.55) 4.85*** (2.52–9.35) 4.87** (1.10–21.46) 4.54** (1.04–19.93)
Control for pre-exposure 
period (14 days) 4.74*** (2.38–9.44) 4.85*** (2.52–9.34) 4.80** (1.09–21.18) 4.48** (1.02–19.65)
Exclude who died within 
90 days of AMI/stroke 4.70*** (2.27–9.75) 4.25*** (2.06–8.80) 3.32 (0.42–26.18) 3.01 (0.39–23.46)
Robustness check for 
Model 1
First cancer events only
N = 106
All cancer events only
N = 146




Exposure 1–14 days 1.77 (0.65–4.85) 1.28 (0.47–3.46) 1.47 (0.46–4.63) 1.21 (0.45–3.26)
Table 3.  Models with interaction for comparing relative incidence ratios for AMI/stroke after LRTI exposure 
among subgroups. ***Significant at 1%.
Model All AMI events First AMI events only All stroke events First stroke events only
Model 1 with gender interaction
Exposure 1–14 7.41*** (3.10–17.70) 6.83*** (2.87–16.25) 3.33 (0.42–26.23) 3.41 (0.43–26.88)
Exposure 1–14 × male 0.39 (0.09–1.67) 0.51 (0.13–1.93) 2.21 (0.11–42.81) 2.56 (0.13–50.49)
Model 1 with age interaction
Exposure 1–14 6.74*** (2.64–17.21) 5.86*** (2.31–14.86) NA NA
Exposure 1–14 × age ≥ 65 years 0.53 (0.13–2.12) 0.72 (0.20–2.65) NA NA
Model 1 with indigenous interaction
Exposure 1–14 3.97*** (1.59–9.91) 4.45*** (1.92–10.32) NA NA
Exposure 1–14 × indigenous 1.69 (0.42–6.79) 1.30 (0.34–4.95) NA NA
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results also showed that an elevated incidence ratio is still present up to 3-months. However, the magnitude of 
relative risks was smaller than RIRs for 14-day period, which was in line with our expectations. Our findings 
are consistent with the previous studies suggesting respiratory infections, including pneumonia and influenza, 
might act as triggers for AMI and stroke  events14,15. These studies recorded significant increases in incidence 
risks of stroke following infections with Streptococcus pneumonia and influenza.
We also tested whether incidence ratios are heterogeneous with respect to sociodemographic characteristics, 
such as gender, age, and indigenous status. Although we reported the differences in the incidence ratio point 
estimates, the analyses had low power to identify statistically significant differences between the subsamples. 
This is similar to the previous studies where confidence intervals for the estimated incidence ratios stratified by 
age overlapped and no evidence of significant heterogeneity were  reported14,15.
From the clinical perspective, both AMI and stroke occur due to atherosclerotic disease and, particularly, 
unstable vascular plaques. The altered physiology of sepsis with an increased sympathetic tone, vasoconstriction, 
increased myocardial oxygen demands and hypovolaemia play major roles in precipitation of acute vascular 
events, and places increased demand on the  heart16–18. Additionally, atherosclerotic disease has an inflammatory 
component that is enhanced by severe infection due to LRTI and other infections including urinary tract infec-
tions contribute to increased risk of these vascular events through a number of complex  mechanisms19. Sepsis 
induces a procoagulant state through the action of cytokines, disturbance in coagulation pathway factors, acti-
vated platelets, and innate immune system  activation20. Prevention of AMI and stroke that occur hyper-acutely 
in sepsis due to LRTI relies on restoring the normal physiological state with fluid resuscitation, supplemental 
oxygen, and antibiotics. Other interventions may be useful in the prevention of vascular events during the 
2–4 weeks after LRTI. Long term use of aspirin has been associated with reduced cardiovascular events in cohort 
studies of patients with  pneumonia21.
A randomised controlled trial of aspirin for the prevention of acute coronary syndrome (ACS) following 
pneumonia was reported in  201322. This Turkish trial of 185 patients showed a large reduction in the incidence 
of ACS in patients randomised to 300 mg aspirin daily in the month after a pneumonic illness. Death due to 
acute coronary syndrome was also significantly reduced. This single trial requires validation with a larger study. 
Further analysis of the patients involved in the ANTISEPSIS primary prevention trial may be able to provide more 
evidence of benefit from low-dose aspirin for the prevention of coronary vascular diseases following pneumonia 
and other sepsis leading to  hospitalisation23.
Statin drugs have also been studied and may reduce ACS due to lipid-lowering and their immunomodulating 
 effects24. A meta-analysis of observational studies shows that the use of statins reduces all-cause mortality after 
 pneumonia25. Influenza vaccination appears to reduce mortality due to  ACS26. Pneumococcal vaccination has 
also been associated with reduced risk of acute coronary syndromes and associated  mortality27.
We are cognisant of a number of limitations of our study. Firstly, we did not include the AMI or strokes that 
occurred during the admission for pneumonia because we were unable to calculate the time interval between 
these two events if they occurred in the same hospitalisation episode. This potentially underestimated the magni-
tude of the increased risk of AMI and stroke. The absence of these data also made it difficult to study the periods 
of risk less than 1 week. Overall, a total of 112 cases of AMI and seven cases of stroke were recorded in discharge 
ICD-10-AM coding as other diagnoses during a hospital episode where pneumonia was the primary diagnosis.
Secondly, information on subsequent hospitalisations would not be available for patients who may have 
moved to the catchment of another health services after having an LRTI event. This may lead to the underestima-
tion of our relative risk ratios. However, with the large catchment and no other tertiary hospital within 1300 km, 
we believe the underestimate will be relatively small compared with other hospitals.
Lastly, the numbers of stroke events included in the study were small and, although significant, the associa-
tion with preceding LRTI should be interpreted with care as the confidence intervals around the point estimates 
are wide. While the data used were from a single hospital, potentially limiting generalisation to the Australian 
population, other similar results from international studies support this result being a true association.
This self-controlled cohort study of patients admitted to an Australian tertiary hospital demonstrates an 
association between hospitalisation with severe lower respiratory tract infection and increased risk of cardiovas-
cular disease in the 2 weeks post-discharge. There are data from observational cohort studies and randomised 
controlled trials of benefits of aspirin, statins, influenza and pneumococcal vaccination in the prevention of 
cardiovascular disease associated with pneumonia. On this basis, it is imperative that optimal secondary preven-
tion strategies are deployed in patients with severe pneumonia and influenza.
Methods
Data sources and study design. The data used in this study is derived from a large relational database 
described in Eisen et al.28. The database includes detailed information on the cohort of patients admitted to 
Townsville University Hospital (TUH) with LRTI between January 1, 2006, and December 31, 2016. TUH is a 
regional tertiary hospital in Australia providing care for 670,000 people in Northern Australia. The complete 
database includes diagnostic codes (ICD-10-AM) for 41,367 patients with 378,487 admissions.
Exposure. We included in our study all inpatients with a primary diagnosis of viral and bacterial pneumonia 
defined by J09–J18 ICD-10-AM discharge codes. We limit our exposure dates to the period between January 1, 
2007, and December 31, 2015, to allow each patient to have a 2-year interval (from 1 year before and 1 year after 
the exposure date) in which we observe AMI and stroke events.
Outcome. The outcome of interest in this study was all incidence of AMI (based on ICD-10-AM codes) 
codes: I21-I22 and ischaemic stroke (I63, G46) between January 1, 2006 and December 31, 2016 occurring in 
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hospitalised patients. The risk event consisted of bacterial pneumonia or influenza occurring as the primary 
diagnosis for patient hospital admissions. For patients with more than one incident of AMI/stroke within the 
exposure window, we created two scenarios. The first scenario includes only single incidents of AMI or stroke 
(the first event for each patient). The second scenario includes the count of all events a patient experienced dur-
ing the observation period.
We define the observation period for each patient as the interval 1 year before and 1 year after the discharge 
date of the first LRTI exposure. To be included in the study, patients required at least one recorded inpatient AMI/
stroke episode within this 2-year period. In the case where an AMI/stroke admission happened within 30 days 
from the discharge date of the previous episode, we consider the subsequent episode as a related admission and 
do not count it as a separate event. The schematic of the study design is presented in Fig. 3.
We note that few patients died within the 50-week period after the end of the exposure period. For these 
patients, the baseline period became smaller, and the observation period ended at the corresponding time of 
death. Because our study outcomes (AMI and stroke) carry a high mortality risk, the impact of death on the 
observation periods can create bias in the results, although it is often reported to be  small29. We test the robustness 
of our results by running a likelihood ratio test for the models with and without interaction between exposure 
and censoring indicators. We conclude that this censoring approach does not produce any statistically significant 
differences and do not cause bias to our results.
Modelling strategy. We used separate conditional fixed-effects Poisson regressions to compute parameter 
estimates and interpret the results in terms of incidence rate ratios, i.e. relative incidence of AMI/stroke in “at-
risk” or exposure periods to the incidence in baseline or unexposed periods. Because this methodology relies on 
within-person comparisons, it eliminates the problem of time-invariant (i.e. fixed) confounders. This is advanta-
geous as some confounding factors may not be adequately recorded or captured in the dataset. Furthermore, we 
account for the time-varying confounders by including controls for calendar months.
Although patient to patient variability (and potential confounding) is avoided by including all individuals 
in both at risk and control groups, yet some individual-based factors could still modify the risk of the outcome 
given the exposure.We perform additional analyses by including interaction terms to examine whether heteroge-
neous effects due to age at AMI/stroke event (< 65 years vs ≥ 65 years), gender (male vs female), and indigenous 
status (Indigenous vs non-Indigenous) are significant. The likelihood ratio test was used to test the importance 
of interaction terms.
Experiencing an AMI/stroke may change the probability of subsequent AMI/stroke episodes that might vio-
late the independence of events assumption for the self-controlled case series methodology. To account for this 
potential problem, we perform a robustness check by running separate analyses for first records of AMI/stroke 
and all AMI/stroke episodes. We also sought to study the specificity of the demonstrated relationship between 
the at-risk LRTI disease and AMI/stroke outcome. In this regard, we analysed whether a similar association was 
present between LRTI and diabetes/cancer, both common non-infective causes for hospitalisation, using the 
same self-controlled cohort study methodology.
Ethics approval. This study was part of the project, HREC/16/QTHS/221, approved by the Townsville 
Hospital and Health Service (THHS) Human Research Ethics Committee. A waiver of consent for access to 
anonymised data was approved under the Queensland Public Health Act (RD007802). The anonymised second-
ary data extraction does not require patient recruitment. All methods regarding human use in the manuscript 
were carried out in accordance with relevant guidelines and regulations.
Figure 3.  Diagram of the study design.
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